Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition - Narrative (Details)

v3.20.2
Revenue Recognition - Narrative (Details) - USD ($)
3 Months Ended 6 Months Ended 33 Months Ended 66 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2020
Dec. 31, 2019
Disaggregation of Revenue [Line Items]              
Prior period performance obligation revenue recognized     $ 200,000 $ (14,300,000)      
Overpayment reimbursement liability $ 21,400,000   21,400,000   $ 21,400,000 $ 21,400,000 $ 27,300,000
Revenue recognized         0    
Total revenues 301,207,000 $ 226,368,000 512,674,000 448,820,000      
Contract liability 17,700,000   17,700,000   $ 17,700,000 17,700,000 $ 21,800,000
Rayaldee              
Disaggregation of Revenue [Line Items]              
Revenue recognized 8,600,000 5,700,000 18,600,000 11,500,000      
Total revenues 22,876,000   45,559,000        
Transfer of intellectual property and other              
Disaggregation of Revenue [Line Items]              
Total revenues 20,880,000 19,230,000 30,433,000 37,490,000      
Pfizer | Products              
Disaggregation of Revenue [Line Items]              
Revenue recognized           $ 0  
Pfizer | Products | Transfer of intellectual property and other              
Disaggregation of Revenue [Line Items]              
Total revenues 13,900,000 $ 18,200,000 $ 22,700,000 $ 35,600,000      
BioReference | Products | Transfer of intellectual property and other              
Disaggregation of Revenue [Line Items]              
Total revenues $ 6,200,000